Vir’s ‘sock gains on early results from clinical trials for its hepatitis B treatment candidate


Shares of Vir Biotechnology Inc.
gained 3.1% in premarket trading on Friday after the company shared positive data from mid-stage and early-stage clinical trials for its experimental hepatitis C treatments. One candidate, VIR-2218, was tested subcutaneously in 32 patients with chronic hepatitis B infections. The other, VIR-3434, enrolled 40 patients in a Phase 1 clinical trial. Vir’s stock is up 85.2% so far this year, while the S&P 500
has gained 13.0%.


- Advertisement -

Leave A Reply

Your email address will not be published.